Patients with carcinoid tumors | Entire cohort | |||||||
Incidence per patient | Incidence per treatment cycle | Incidence per patient | Incidence per treatment cycle | |||||
Adverse event | No. (n = 20) | % | No. (n = 43) | % | No. (n = 31) | % | No. (n = 78) | % |
Leukopenia (WBC) | ||||||||
Grade 1 | 2 | 10.0 | 8 | 18.6 | 14 | 45.1 | 20 | 25.6 |
Grade 2 | 9 | 45.0 | 15 | 34.9 | 14 | 45.1 | 18 | 23.0 |
Grade 3 | 5 | 25.0 | 8 | 18.6 | 6 | 19.3 | 12 | 15.3 |
Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Thrombocytopenia (PLT) | ||||||||
Grade 1 | 5 | 25.0 | 5 | 11.6 | 9 | 29.0 | 11 | 14.1 |
Grade 2 | 1 | 5.0 | 3 | 7.0 | 3 | 9.6 | 4 | 5.1 |
Grade 3 | 3 | 15.0 | 5 | 11.6 | 3 | 9.6 | 5 | 6.4 |
Grade 4 | 1 | 5.0 | 1 | 2.3 | 1 | 3.2 | 1 | 1.2 |
Significant (grade 3 or 4) | ||||||||
WBC | 5 | 25.0 | 8 | 18.6 | 6 | 19.3 | 12 | 15.3 |
PLT | 4 | 20.0 | 6 | 14.0 | 4 | 12.9 | 6 | 7.6 |
Nonhematologic | ||||||||
Nausea (grade 1 or 2) | 8 | 40.0 | 10 | 23.3 | 14 | 45.2 | 22 | 28.2 |
Vomiting (grade 1 or 2) | 2 | 10.0 | 2 | 4.7 | 5 | 16.1 | 5 | 6.4 |
Hypertension* (grade 1 or 2) | 1 | 5.0 | 1 | 2.3 | 2 | 6.4 | 3 | 3.8 |
Complications | ||||||||
Hospitalization | 0 | 0 | 0 | 0 | 1 | 3.2 | 1 | 1.2 |
GCS-F stimulation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Transfusion | 0 | 0 | 0 | 0 | 1 | 3.2 | 1 | 1.2 |
Discontinuation of 131I-MIBG treatment | 0 | 0 | 0 | 0 | 1 | 3.2 | 1 | 1.2 |
↵* Transient hypertension during 131I-MIBG infusion.
WBC = white blood cells; PLT = platelets; GCS-F = granulocyte colony-stimulating factor.